Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating Divesiran In 21 Phlebotomy-Dependent Patients With Polycythemia Vera At EHA 2026 Annual Congress.

Loading news article.

Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating Divesiran In 21 Phlebotomy-Dependent Patients With Polycythemia Vera At EHA 2026 Annual Congress. | WAPE

Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating Divesiran In 21 Phlebotomy-Dependent Patients With Polycythemia Vera At EHA 2026 Annual Congress.

Article summary

Related companies

Comments —